Cancer Immunotherapy Toxicity Evaluation (CITE) Program
Immunotherapy harnesses the patient's own immune system to help fight their cancer. These cutting-edge treatments – which include cancer vaccines, cellular therapies, immune checkpoint inhibitors and other drugs – can sometimes overstimulate the immune system, leading to side effects that range from minor to serious. Some are easily managed with steroids while others require care from experts in specific organ systems and immunosuppression (curbing the immune response). Sometimes these side effects necessitate suspending the patient's cancer treatment.
The UCSF Cancer Immunotherapy Toxicity Evaluation (CITE) Program cares for patients with complex, difficult-to-treat side effects from immunotherapy. If you're experiencing these side effects, getting a correct diagnosis and access to appropriate providers can be challenging. The CITE Program brings together a dedicated, experienced team of oncologists and other specialists who collaboratively manage your condition.
Our care team also serves as a resource for doctors outside UCSF seeking second opinions on their patients with immunotherapy-related side effects. The CITE Program is one of a kind in the Bay Area and one of the first of its kind in the nation. In addition to patient care, our team is dedicated to advancing research on immunotherapy through clinical trials (studies of promising new treatments) and the banking of blood and tissue specimens. Our program works closely with other specialty groups at UCSF, including the Cancer Immunotherapy Program, which evaluates treatments in early phases of development.
Our locations (1)
Clinical trials
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
The investigators will identify the genes predictive of response to anti-PD-1 therapy by testing for significant associations across expression rates of each gene and response/resistance, within a hurdle-Gaussian mixed-effect fram...
Recruiting
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Ce...
TIICs will be analyzed in pre- and post-pembrolizumab-based treatment tumor specimens. The proportion of participants with a >=2-fold increase (from pre- to post-treatment) in the number of TIICs will be calculated.
Recruiting
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...
Recruiting
Support services
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes
